A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current PD-L1-blocking antibodies is potentially reduced by ‘on-target/off-tumor’ binding to PD-L1 widely...

Descripción completa

Detalles Bibliográficos
Autores principales: Koopmans, Iris, Hendriks, Djoke, Samplonius, Douwe F., van Ginkel, Robert J., Heskamp, Sandra, Wierstra, Peter J., Bremer, Edwin, Helfrich, Wijnand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136863/
https://www.ncbi.nlm.nih.gov/pubmed/30221065
http://dx.doi.org/10.1080/2162402X.2018.1466016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136863/
https://www.ncbi.nlm.nih.gov/pubmed/30221065
http://dx.doi.org/10.1080/2162402X.2018.1466016

Ejemplares similares